During the last session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares were 1.25 million, with the beta value of the company hitting 1.37. At the end of the trading day, the stock’s price was $7.79, reflecting an intraday loss of -8.46% or -$0.72. The 52-week high for the GLUE share is $12.40, that puts it down -59.18 from that peak though still a striking 58.79% gain since the share price plummeted to a 52-week low of $3.21. The company’s market capitalization is $478.60M, and the average intraday trading volume over the past 10 days was 2.05 million shares, and the average trade volume was 2.51 million shares over the past three months.
Monte Rosa Therapeutics Inc (GLUE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. GLUE has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Monte Rosa Therapeutics Inc (GLUE) registered a -8.46% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.46% in intraday trading to $7.79, hitting a weekly high. The stock’s 5-day price performance is -11.78%, and it has moved by -14.68% in 30 days. Based on these gigs, the overall price performance for the year is 68.98%. The short interest in Monte Rosa Therapeutics Inc (NASDAQ:GLUE) is 11.05 million shares and it means that shorts have 8.2 day(s) to cover.
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Statistics show that Monte Rosa Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Monte Rosa Therapeutics Inc (GLUE) shares have gone up 94.26% during the last six months, with a year-to-date growth rate more than the industry average at 43.35% against 17.10.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 51.19M as predicted by 7 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 6.1M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -96.71%. While earnings are projected to return 61.74% in 2024.
GLUE Dividends
Monte Rosa Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Monte Rosa Therapeutics Inc insiders own 0.70% of total outstanding shares while institutional holders control 90.62%, with the float percentage being 91.27%. NEA MANAGEMENT COMPANY, LLC is the largest shareholder of the company, while 122.0 institutions own stock in it. As of 2024-06-30, the company held over 7.69 million shares (or 12.7872% of all shares), a total value of $28.77 million in shares.
The next largest institutional holding, with 5.98 million shares, is of PRICE T ROWE ASSOCIATES INC /MD/’s that is approximately 9.9368% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.36 million.
Also, the Mutual Funds coming in first place with the largest holdings of Monte Rosa Therapeutics Inc (GLUE) shares are Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Price (T.Rowe) New Horizons Fund owns about 3.41 shares. This amounts to just over 5.54 percent of the company’s overall shares, with a $26.53 million market value. The same data shows that the other fund manager holds slightly less at 1.35, or about 2.20% of the stock, which is worth about $10.52 million.
